Insulin Glargine Gla-300 Pediatric Trial Marked Completed

A Phase 4 clinical trial involving insulin glargine was marked completed on October 13, 2026. The trial, registered as NCT07872475, is titled "Randomized Transition to Gla-300 in Pediatric Type 1 Diabetes: CGM-Derived Outcomes." It evaluated a randomized transition to the Gla-300 formulation of insulin glargine in a pediatric population with type 1 diabetes, using continuous glucose monitoring derived outcomes as part of the study design. The trial status is listed as completed as of the update date. Insulin glargine remains an approved compound. This update reflects only the trial status change and does not include specific results or findings. No efficacy or safety conclusions can be drawn from the completion status alone. Additional details about the study design, outcome measures, and any reported results would need to be reviewed directly through the official trial registry listing. Readers interested in the broader context of insulin glargine, including its approved uses and regulatory history, can consult the compound overview for further background information.